T-bet is a transcription factor, one of the control proteins in the cell nucleus that can turn specific groups of genes on ...

At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

Dr Dinesh Pendharkar highlights how CAR T–cell therapy is reshaping cancer care in India by equipping the immune system with ...